SCHEDULE 13G/A: BlackRock Amends Corcept Therapeutics Stake, Maintains 10.9% Passive Ownership

BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, confirming a continued beneficial ownership of 10.9% in Corcept Therapeutics Incorporated as of June 30, 2025.

Summary

• BlackRock, Inc. filed an Amendment No. 4 to its Schedule 13G, updating its beneficial ownership in Corcept Therapeutics Incorporated.
• As of June 30, 2025, BlackRock beneficially owns an aggregate of 11,539,099 shares of Corcept Therapeutics' common stock.
• This ownership represents 10.9% of the total outstanding common stock of Corcept Therapeutics.
• BlackRock holds sole voting power over 11,314,797 shares and sole dispositive power over 11,539,099 shares.
• The filing explicitly states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
• iShares Core S&P Small-Cap ETF, a business unit of BlackRock, Inc., is noted to have an interest of more than 5% in the common stock of Corcept Therapeutics Incorporated.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is routine and indicates a stable, significant passive investment by a major institutional holder, which can be seen as a vote of confidence, but it provides no new operational or financial insights for the issuer.

Positives

• BlackRock, a prominent institutional investor, maintains a significant 10.9% stake in Corcept Therapeutics, indicating continued passive investment interest.
• The filing reaffirms BlackRock's passive investment intent, suggesting stability in its holding without seeking to influence the company's control or operations.

Risks

• This Schedule 13G filing, being a disclosure of passive ownership, does not detail specific operational or financial risks pertaining to Corcept Therapeutics Incorporated.

Future Outlook

This document, a beneficial ownership report, does not provide any forward-looking statements or guidance regarding Corcept Therapeutics Incorporated's future operations, financial performance, or strategic outlook.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

This filing represents a routine disclosure of a large institutional investor's passive stake in a publicly traded biotechnology company. It primarily reflects BlackRock's portfolio management activities across its various funds, rather than specific industry trends or competitive dynamics for Corcept Therapeutics.

Comparison to Industry Standards

• This document is a standard Schedule 13G beneficial ownership filing, which is a common disclosure for institutional investors holding significant passive stakes.
• BlackRock's 10.9% stake in Corcept Therapeutics is a substantial passive investment, consistent with the portfolio composition of large asset managers, particularly those with funds focused on specific market segments like small-cap companies (e.g., iShares Core S&P Small-Cap ETF).

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which may offer some reassurance about institutional interest in the company.

Key Dates

Recommendation

Keywords

Corcept Therapeutics, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Passive Investment, Biotechnology, Pharmaceuticals